Eupraxia Pharmaceuticals 宣布 RESOLVE 试验中 EP-104GI 治疗嗜酸性食管炎的 1 年临床结果为积极
Eupraxia Pharmaceuticals Inc. announced positive results from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). Two-thirds of patients in Cohort 5 maintained clinical remission at 12 months post-treatment. All cohorts showed significant improvements in tissue health, with no serious adverse events reported. Plasma levels of fluticasone remained stable, suggesting EP-104GI could enhance current EoE treatments with a potential once-a-year therapy. Further 12-month data from a larger patient group is expected later this year.
Eupraxia Pharmaceuticals Inc. has announced additional positive clinical data from its ongoing Phase 1b/2a RESOLVE trial, which is evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE). The results, presented from the trial, indicate that 2/3rds of patients in Cohort 5, who received a 48mg dose, remained in clinical remission at 12 months post-treatment. The trial also reported that all cohorts maintained clinically meaningful improvements in tissue health as measured by the EoE Histological Scoring System. No serious adverse events or cases of oral or gastrointestinal candidiasis have been reported to date. Plasma levels of fluticasone remained stable and predictable out to 52 weeks, below levels typically seen with daily asthma inhalers. These findings suggest potential for EP-104GI to enhance the current standard of care for EoE, providing a possible once-a-year therapy. Additional 12-month data from a larger patient set is expected to be reported later this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-005662), on September 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
